The pharmacokinetics of pirtobrutinib

Pirtobrutinib resistance in CLL: early findingsПодробнее

Pirtobrutinib: The next generation of BTK inhibitorsПодробнее

Phase I/II BRUIN update: efficacy of pirtobrutinib in R/R Waldenström's macroglobulinemiaПодробнее

Genomic evolution & resistance to pirtobrutinib in covalent BTK inhibitor pre-treated CLLПодробнее

Extensions of BRUIN investigating pirtobrutinib combinations for time-limited CLL treatmentПодробнее

Understanding the Pharmacokinetics of the TREVICTA® PlanПодробнее

BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLLПодробнее

Clinical Pearl BTK Inhibitors and PirtobrutinibПодробнее

The promise of pirtobrutinib in the treatment of CLLПодробнее

Phase I/II BRUIN study: pirtobrutinib in patients intolerant to a covalent BTK inhibitorПодробнее

Updated results of Phase I/II BRUIN study: pirtobrutinib in covalent BTK inhibitor pretreated MCLПодробнее

BRUIN study cohort update: pirtobrutinib for patients with MCLПодробнее

Ongoing trials investigating the efficacy of pirtobrutinib in CLLПодробнее

Pirtobrutinib for BTK inhibitor-naïve and BTK inhibitor pre-treated R/R MCLПодробнее

NCATS Drug Metabolism and Pharmacokinetic Core — Virtual Lab Tour 2022Подробнее

Updated results from the BRUIN study: pirtobrutinib in the treatment of MCLПодробнее

Pirtobrutinib in R/R FL: results from the BRUIN studyПодробнее

The impact of the approval of pirtobrutinib on the treatment landscape for patients with CLLПодробнее

Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCLПодробнее